Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 3, 2010, Pages 455-466

  Wang, Ying ^a   Rishi, Arun K ^a   Puliyappadamba, Vineshkumar T ^a   Sharma, Sunita ^a   Yang, Huanjie ^b   Tarca, Adi ^b   Dou, Q Ping ^b   Lonardo, Fulvio ^b   Ruckdeschel, John C ^c   Pass, Harvey I ^d   Wali, Anil ^a,e  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Department of Hematology Oncology   (United States)

^d NEW YORK UNIVERSITY   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Bortezomib (Velcade); Gene expression; Malignant pleural mesothelioma

Indexed keywords

BORTEZOMIB; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEASOME; PROTEIN BAX; PROTEIN CARP1; PROTEIN TNFRSF 19; SIGNAL TRANSDUCING ADAPTOR PROTEIN; UNCLASSIFIED DRUG; XIAP ASSOCIATED FACTOR 1; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MESOTHELIOMA; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; WESTERN BLOTTING; APOPTOSIS; BREAST TUMOR; CELL CYCLE; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; FEMALE; PATHOLOGY; PILOT STUDY; TIME; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; BORONIC ACIDS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; DRUG SYNERGISM; FEMALE; FLOW CYTOMETRY; HUMANS; MESOTHELIOMA; PILOT PROJECTS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 77954678999     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1181-8     Document Type: Article

References (30)

1. Antman KH, Pass HI, Schiff PB (2001) Benign and malignant mesothelioma. In: DeVita VTJ, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 6th edn. Lippincott-Raven, Philadelphia, pp 1943-1970
2. Peto J, Decaril A, La Vecchia C, Levi F, Negri E (1999) The European mesothelioma epidemic. Br J Cancer 79:666-672
3. Sterman DH, Kaiser LR, Albelda SM (1999) Advances in the treatment of malignant pleural mesothelioma. Chest 116:504-520
4. Ryan CW, Herndon J, Vogelzang NJ (1998) A review of chemotherapy trials for malignant mesothelioma. Chest 113:66S-73S
5. Goudar RK (2005) New therapeutic options for mesothelioma. Curr Oncol Rep 7(4):260-265
6. Krug LM (2005) An overview of chemotherapy for mesothelioma. Hematol Oncol Clin North Am 19(6):1117-1136
7. Orlowski RZ, Dees EC (2003) Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer. Breast Cancer Res 5:1-7
8. Richardson PG, Hideshima T, Anderson KC (2003) Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 10(5):361-369 Review
9. Dou QP, Goldfarb RH (2002) Bortezomib/P341 (millennium pharmaceuticals) (invited review). IDrugs 5:828-834
10. Kane RC, Bross PF, Farrell AT, Pazdur R (2003) Velcade: U. S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 8:508-513
11. Adams J (2004) The proteosome: a suitable antineoplastic target. Nat Rev Cancer 4:349-360
12. Rishi AK, Zhang L, Boyanapalli M, Wali A, Mohammad RM, Yu Y, Fontana JA, Hatfield JS, Dawson MI, Majumdar A P N, Reichert U (2003) Identification and characterization of a Cell-Cycle and Apoptosis Regulatory Protein (CARP)-1 as a novel mediator of apoptosis signaling by Retinoid CD437. J Biol Chem 278:33422-33435
13. Shao Z, Browning JL, Lee X, Scott ML, Shulga-Morskaya S, Allaire N, Thill G, Levesque M, Sah D, McCoy JM, Murray B, Jung V, Pepinsky RB, Mi S (2005) TAJ/TROY, an orphan TNF receptor family member, binds Nogo-66 receptor 1 and regulates axonal regeneration. Neuron 45:353-359
14. Liston P, Fong WG, Kelly NL, Toji S, Miyazaki T, Conte D, Tamai K, Craig CG, McBurney MW, Korneluk RG (2001) Identification of XAF1 as an antagonist of XIAP anti-Caspase activity. Nat Cell Biol 3(2):128-133
15. Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, Carbone M, Webb C, Wali A (2005) Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 353(15):1564-1573
16. Smyth GK, Limma L (2005) Liner models for microarray data. In: Gentleman R, Carey V, Duoit S, Irizarry R, Huber W (eds) Bioinformatics and computational biology solutions using R and bioconductor. Springer, New York, pp 397-420
17. Tarca AL, Carey VJ, Chen XW, Romero R, Drãghici S (2007) Machine learning and its applications to biology. PLoS Comput Biol 3: e116
18. Wali A, Morin PJ, Hough CD, Lonardo F, Seya T, Carbone M, Pass HI (2005) Identification of intelectin overexpression in malignant pleural mesothelioma by serial analysis of gene expression (SAGE). Lung Cancer 48(1):19-29
19. Sartore-Bianchi A, Gasparri F, Galvani A, Nici L, Darnowski JW, Barbone D, Fennell DA, Gaudino G, Porta C, Mutti L (2007) Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res 13(19):5942-5951
20. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC (1994) Cleavage of poly (ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 371:346-347
21. Rishi AK, Zhang L, Yu Y, Jiang Y, Nautiyal J, Wali A, Fontana JA, Levi E, Majumdar A P N (2006) Cell cycle and apoptosis regulatory protein (CARP)-1 is involved in apoptosis signaling by epidermal growth factor receptor. J Biol Chem 281:13188-13198
22. Kim JH, Yang CK, Heo K, Roeder RG, An W, Stallcup MR (2008) CCAR1, a key regulator of mediator complex recruitment to nuclear receptor transcription complexes. Mol Cell 31:510-519
23. Ou CY, Kim JH, Yang CK, Stallcup MR (2009) Requirement of cell cycle and apoptosis regulator 1 for target gene activation by Wnt and {beta}-catenin and for anchorage-independent growth of human colon carcinoma cells. J Biol Chem 284(31):20629-20637
24. Yuan BZ, Chapman JA, Reynolds SH (2008) Proteasome inhibitor MG132 induces apoptosis and inhibits invasion of human malignant pleural mesothelioma cells. Transl Oncol 1(3):129-140
25. Gordon GJ, Mani M, Mukhopadhyay L, Dong L, Yeap BY, Sugarbaker DJ, Bueno R (2007) Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma. J Pathol 211(4):439-446 (Pubitemid 46332555)
26. Gordon GJ, Mani M, Maulik G, Mukhopadhyay L, Yeap BY, Kindler HL, Salgia R, Sugarbaker DJ, Bueno R (2008) Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol 61(4):549-558
27. Borczuk AC, Cappellini GC, Kim HK, Hesdorffer M, Taub RN, Powell CA (2007) Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors. Oncogene 26(4):610-617
28. Fennell DA, Chacko A, Mutti L (2008) BCL-1 family regulation by the 20S proteasome inhibitor bortezomib. Oncogene 27:1189-1197
29. Morohashi S, Kusumi T, Sato F, Odagiri H, Chiba H, Yoshihara S, Hakamada K, Sasaki M, Kijima H (2007) Decreased expression of claudin-1 correlates with recurrence status in breast cancer. Int J Mol Med 20:139-143
30. Tsukita S, Furuse M, Itoh M (2001) Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2:285-293